Quick Takeaways:
- Merck Animal Health has received FDA approval for an expanded label of Bravecto Quantum, adding protection against Asian longhorned tick and Gulf Coast tick. The product is a single, veterinarian-administered injectable offering extended parasite control in dogs
- With this update, Bravecto Quantum now delivers 12 months of protection against multiple tick species, including Ixodes scapularis, Dermacentor variabilis, Rhipicephalus sanguineus, and the newly added ticks, along with 8 months of coverage against lone star ticks, plus flea treatment and prevention, reinforcing its position as a long-acting parasiticide
- The once-yearly injectable format supports improved compliance and uninterrupted protection, addressing the evolving parasite landscape as tick species expand geographically. Available exclusively through veterinarians, the label expansion strengthens Merck’s leadership in long-duration, convenient parasite protection solutions for dogs
Why It Matters?
By extending Bravecto Quantum’s label to cover Asian longhorned and Gulf Coast ticks for a full 12 months, Merck further differentiates the product as the longest‑lasting, broadest‑spectrum injectable parasiticide available exclusively through veterinarians.
The once‑yearly, in‑clinic injection model supports higher real‑world compliance and helps vets proactively manage the geographic spread of emerging tick species, reinforcing Merck’s leadership in convenient, long‑duration parasite protection for dogs.
Source: Businesswire
